Opthea Limited (OPT)
Opthea Limited
650 Chapel Street
Suite 0403 Level 4
South Yarra, VIC 3141
Australia
61 3 9826 0399
https://opthea.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 24
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Megan Baldwin M.A.I.C.D., MAICD, Ph.D. | Founder, Chief Innovation Officer & Executive Director | 599.73k | N/D | 1975 |
| Ms. Judith J. Robertson B.A., M.B.A. | Chief Commercial Officer | 588.59k | N/D | 1961 |
| Ms. Karen Adams CPA | VP of Finance & Company Secretary | 305.14k | N/D | 1972 |
| Dr. Frederic Guerard M.S., Pharm.D. | Chief Executive Officer | N/D | N/D | 1973 |
| Mr. Peter F. Lang M.B.A. | Chief Financial Officer | N/D | N/D | 1973 |
| Ms. Sarika Gulhar Ph.D. | Executive Director of Human Resources | N/D | N/D | N/D |
| Dr. Michael Gerometta Ph.D. | Head of Chemistry, Manufacturing & Controls Development | 131.18k | N/D | 1965 |
| Mr. Bruno Gagnon BPHARM, M.Sc. | Senior Vice President of Global Clinical Operations | N/D | N/D | 1969 |
| Dr. Kenneth Sall | Chief Medical Officer | N/D | N/D | N/D |
| Dr. Fang Li Ph.D. | Senior Vice President of Regulatory Affairs | N/D | N/D | N/D |
Descripción
Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead product candidate is Sozinibercept (OPT 302), a soluble form of vascular endothelial growth factor receptor-3 VEGFR-3, currently under Phase 3 clinical development as a novel therapy for wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.
Gestión corporativa
La calificación ISS Governance QuickScore de Opthea Limited a partir del 1 de mayo de 2024 es 9. Las puntuaciones principales son Auditoría: 10; Junta: 6; Derechos del accionista: 10; Compensación: 10.
